Evolution of pancreatic ductal adenocarcinoma diagnosis during the last decade.

Medientyp: E-Artikel

Titel: Evolution of pancreatic ductal adenocarcinoma diagnosis during the last decade

Beteiligte: Jiménez Rodríguez, Roberto; Gonzalez Caraballo, Irene; Martín Lozano, Rocío; Alva Bianchi, Manuel; de Lucas, Mónica Benavente; Gómez, María Palma; Muñoz, Marc Ariant Cañete; Lobato Delgado, Bárbara; Tirado Anula, Victoria; Morón García, Blanca; Ruiz Zamorano, Magdalena; Marquez-Rodas, Ivan; Echavarria Diaz Guardamino, Isabel; Torres Pérez-Solero, Gabriela; Calvo Ferrándiz, Aitana; Ortega, Laura; Soria, Jose Manuel; Garcia-Alfonso, Pilar; Martin, Miguel; Muñoz Martín, Andrés J.

Erschienen: American Society of Clinical Oncology (ASCO), 2023

Sprache: Englisch

DOI: 10.1200/jco.2023.41.4_suppl.670

ISSN: 0732-183X; 1527-7755

Schlagwörter: Cancer Research ; Oncology

Entstehung:

Anmerkungen:

Beschreibung: 670 Background: Pancreatic Ductal Adenocarcinoma (PDAC) has historically been an important diagnostic and therapeutic challenge. The multidisciplinary approach and new diagnostic techniques’ implementation have modified this process. Methods: We conducted a retrospective analysis based on clinical data of patients with PDAC between the years 2010 to 2021, analyzing the diagnosis and initial treatment evolution. Results: 673 patients between 2010-2021 with a suspected diagnosis of pancreatic adenocarcinoma were reviewed. Most of them were metastatic (n=362; 53.8%), followed by locally advanced unresectable (n=166; 24.7%) and resectable or borderline resectable (n=145; 21.5%). Regarding the pathological diagnosis, it was not possible in 62 patients (9.2%), varying over time from 21.2% in 2010-2012 to 1% in 2019-2021 (p<0,0001). Moreover, the number of biopsies has decreased with a mean number of biopsies to obtain a pathological diagnosis of 1.55 (2010-2012) vs 1.31 (2019-2021). During this last period, most of the diagnoses were made by cytological analysis (61.4%; n=121). Specifically in the 2019-2021 patients subgroup, we found that 18 NGS (9,1%) were performed in this period (solid tumor), with 4 patients having actionable mutations (22.2%; 3 KRAS G12C). Germline (g) mutational panels were carried out in 89 patients, finding only 9 positive cases (10.1%), being 3 of them gBRCA1/2 mutated (3,4%). In our study, a decrease in palliative management was evidenced over time. In 2010-2012, 28,8% of patients received exclusively palliative care against 9,6% in 2019-21 (p< 0.0001). An increase in PDAC diagnosis was observed since 2010, 44 patients/year in 2010-12 vs. 66 patients/year in 2019-21 (including COVID-19 pandemic period). All previous results are summarized. Conclusions: The diagnosis of PDAC has changed throughout the last decade, increasing the percentage of patients with a pathological diagnosis without increasing the number of invasive procedures. The number of patients suitable for anti-cancer therapy has also increased among time. In our cohort, the implementation of molecular testing would change the therapeutic approach in more than 20% of patients.[Table: see text]

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: